Skip to content
Intrinsic value · Buy/Sell verdict · scores — free· 500 Nifty 500 stocks· EOD 2026-06-15

Bayer Cropscience Ltd.

BAYERCROP · NSE · Basic Materials

₹4,291.3
+43.70 (+1.03%)
Our verdict
Buy61/100
Quality73
Valuation84
Momentum18
Financial trend50
Intrinsic value
Our fair value
₹5,658.25
Undervalued by 32%
Price ₹4,291.3Range ₹4,809.51₹6,506.99

With a 20% margin of safety, our buy-below price is ₹4,526.6.

A
Financial health 100/100
Altman Z 6.29 · Safe zone

Piotroski F-score 4/9 — quality of earnings & balance sheet.

Investability checklist

Passed 9 of 13 checks69/100
  • ROE above 15%23.7%
  • Low debt (D/E < 0.5)0.03x
  • Positive free cash flow
  • Revenue growth > 10%5%
  • Earnings growing13%
  • Net margin ≥ 10%12.1%
  • Current ratio > 1.51.92
  • Below our fair value
  • Margin of safety ≥ 20%
  • Above 200-day average
  • Above 50-day average
  • Positive 1-year return
  • Altman Z in safe zoneZ 6.29
  • Piotroski ≥ 74/9

1-year price

EOD · 2026-06-15
1W
+0.2%
1M
-1.3%
3M
-4.7%
6M
-2.5%
1Y

Our scores

Durability73
Valuation67
Momentum18
Analyst consensus target ₹5,221.83 (+22%) · 6 analysts

Key fundamentals

Market cap
₹19,286 Cr
P/E ratio
28.0
P/B ratio
6.50
EPS (TTM)
₹153.34
ROE
23.7%
Debt / Equity
0.03x
Profit margin
12.1%
Free cash flow
₹960 Cr
52-week high
₹6,316.53
-32.06% from high
52-week low
₹4,218.8
Dividend yield
2.9%
Beta
0.21

SWOT snapshot

Strengths

  • Strong return on equity (23.7%).
  • Lightly leveraged balance sheet.
  • Financially solid — Altman Z 6.29.

Weaknesses

  • Price below its 200-day moving average (downtrend).

Opportunities

  • Trading in our value buy zone versus sector peers.
  • Trades ~32% below our estimated fair value.

About Bayer Cropscience Ltd.

Bayer CropScience Limited engages in the manufacture, sale, and distribution of insecticides, fungicides, herbicides, and various other agrochemical products and hybrid corn seeds in India, Germany, Bangladesh, and internationally. It provides medicines in the therapeutic areas of cardiology, gynecology, diabetes, oncology, and ophthalmology; and computed tomography, X-Ray, and magnetic resonance imaging devices. In addition, the company offers consumer health products that a

More in Chemicals

Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.